Delcath Systems (NASDAQ:DCTH) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Delcath Systems (NASDAQ:DCTH) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

Separately, Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Delcath Systems currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Delcath Systems Stock Performance

Delcath Systems stock opened at $13.10 on Tuesday. The firm has a market capitalization of $452.21 million, a PE ratio of 1,310.00 and a beta of 0.49. Delcath Systems has a one year low of $8.12 and a one year high of $13.74. The stock’s 50 day moving average price is $11.57 and its 200 day moving average price is $10.48.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. The company had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. On average, analysts forecast that Delcath Systems will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently bought and sold shares of DCTH. Deutsche Bank AG grew its position in shares of Delcath Systems by 5.4% in the 4th quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock worth $244,000 after acquiring an additional 1,248 shares in the last quarter. California State Teachers Retirement System bought a new position in shares of Delcath Systems in the 2nd quarter worth about $26,000. Intech Investment Management LLC boosted its holdings in shares of Delcath Systems by 13.1% in the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after buying an additional 2,035 shares during the period. AWM Investment Company Inc. raised its stake in Delcath Systems by 3.9% during the fourth quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock worth $606,000 after acquiring an additional 2,279 shares during the period. Finally, Royal Bank of Canada boosted its stake in Delcath Systems by 14.8% in the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after acquiring an additional 2,364 shares during the period. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.